F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim |
| August 04, 2022 | August 2022 Bond Updates |
|
New Investment from Forbion and Sofinnova Partners MANCHESTER, England, Aug. 4, 2022 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections with a high unmet medical... |
| View more at: https://www.prnewswire.com:443/news-releases/f2g-announces-70-million-financing-to-advance-development-and-commercialization-of-new-antifungal-agent-olorofim-301599295.html |
| Related News |